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Introduction:  Stem  cell  transplantation  has  been  used  for many  years  to treat  haematological  malig-
nancies  that  could  not  be  cured  by  other  treatments.  Despite  this  medical  breakthrough,  mortality  rates
remain high.  Our  purpose  was  to  evaluate  labour  productivity  losses  associated  with  premature  mortality
due to blood  cancer  in  recipients  of  stem  cell  transplantations.
Methods: We  collected  primary  data  from  the  clinical  histories  of  blood  cancer  patients  who had  under-
gone  stem  cell  transplantation  between  2006  and  2011  in two  Spanish  hospitals.  We  carried  out  a
descriptive  analysis  and  calculated  the years  of  potential  life  lost  and  years  of  potential  productive  life
lost.  Labour  productivity  losses  due  to  premature  mortality  were  estimated  using  the  Human  Capital
method. An  alternative  approach,  the  Friction  Cost  method,  was  used  as part  of the  sensitivity  analysis.
Results:  Our ﬁndings  suggest  that,  in  a population  of 179  transplanted  and  deceased  patients,  males  and
people  who  die  between  the ages  of 30 and  49  years  generate  higher  labour  productivity  losses.  The
estimated  loss  amounts  to over  D 31.4 million  using  the  Human  Capital  method  (D 480,152  using  the
Friction  Cost  method),  which  means  an  average  of D  185,855  per  death.  The  highest  labour  productivity
losses  are  produced  by leukaemia.  However,  lymphoma  generates  the  highest  loss  per  death.
Conclusions:  Further  efforts  are needed  to reduce  premature  mortality  in  blood  cancer  patients  under-
going  transplantations  and  reduce  economic  losses.
© 2014  SESPAS.  Published  by  Elsevier  España,  S.L.U.  All  rights  reserved.
Pérdidas  de  productividad  por  mortalidad  prematura  debido  a  una  neoplasia
hematológica:  estudio  basado  en  pacientes  sometidos  a  un  trasplante  de
células  madre
alabras clave:
ostes indirectos
roductividad laboral
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nfermedades hematológicas malignas
rasplante de células hematopoyéticas
r  e  s  u  m  e  n
Introducción:  Durante  muchos  an˜os  el  trasplante  de  células  madre  se ha  usado  para  tratar  neoplasias
hematológicas  que  no  podrían  haber  sido  curadas  mediante  otras  terapias.  A  pesar  de  este  avance  médico,
la ratio  de  mortalidad  es  aún elevada.  Nuestro  objetivo  es evaluar  las  pérdidas  de  productividad  laboral
por  mortalidad  prematura  debido  a una  neoplasia  hematológica  en  receptores  de  trasplante  de  células
madre.
Métodos:  Se  recogieron  datos  primarios  de  las historias  clínicas  de  pacientes  con  neoplasia  hematológica,
trasplantados  durante  los  an˜os 2006  y 2011  en  dos  hospitales  espan˜oles.  Se realizó  un  análisis  descriptivo
y  se  calcularon  los an˜os  potenciales  de  vida  y los an˜os  potenciales  de  vida  laboral  perdidos.  Las  pérdidas
de  productividad  laboral  se estimaron  usando  el método  del  Capital  Humano.  El  método  de  los  Costes  de
Fricción  se  empleó  como  parte  del análisis  de  sensibilidad.
Resultados: En una  población  de  179  pacientes  trasplantados  y fallecidos,  se dan  mayores  pérdidas  de
productividad  laboral  en  varones  y en  personas  de edades  comprendidas  entre  los  30  y  49  an˜os.  La pérdida
estimada  está  por  encima  de  D 31.4  millones  usando  el  método  del  Capital  Humano  (D 480,152  usando
el  método  Costes  Fricción),  lo que  signiﬁca  una  pérdida  media  de  D 185,855  por persona  fallecida.  Las
mayores  pérdidas  globales  son generadas  por  la leucemia.  Sin  embargo,  el  linfoma  genera  las  mayores
pérdidas  por  fallecimiento.
Conclusiones: Mayores  esfuer
trasplantados  por  neoplasia  he
©  2014  SES
∗ Corresponding author. Applied Economic Department, School of Economics and Busin
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213-9111/© 2014 SESPAS. Published by Elsevier España, S.L.U. All rights reserved.zos  son  necesarios  para  reducir  la  mortalidad  prematura  de pacientes
matológica  y reducir  el  impacto  económico  y social  asociado  a la misma.
PAS.  Publicado  por  Elsevier  España,  S.L.U.  Todos  los derechos  reservados.
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The attributable annual number of deaths worldwide due to
ancer is predicted to rise from 7.6 million in 2008 to 13 million
n 2030.1 The International Agency for Research of Cancer (IARC)
stimated that 94.4 thousands deaths would occur in 2012 due to
aematological malignancies (or blood cancer) in the 27 countries
f the European Union (7.49% incidence rate).2 Spain follows a
imilar trend, with blood cancer (taking into account leukaemia,
ymphoma and multiple myeloma) being the fourth most com-
on  cause of death among all types of cancers3 having caused
n estimated 7.4 thousand deaths in 2012 which means a rate of
.24%.2
Because of this high mortality rate, the development and pro-
ressive evolution of haematopoietic stem cell transplantation
HSCT) in recent decades has been an important medical advance.
SCT has become an effective treatment for malignant and benign
aematological diseases that could not be cured by other therapies,
llowing for an increasing number of patients to become long-term
urvivors.4,5 It is an essential part of the therapeutic strategy which
s clinically recommended for blood cancer patients whose clinical
ondition indicates transplantation, are less than 65 years old (occa-
ionally it can be higher) and are free of severe co-morbidities.4 In
pain, throughout Europe, its use has increased in a linear trend. In
013, 2,945 transplantations were carried out in Spain in compari-
on with 1,974 transplantations in 2006.6 However, HSCT remains
ssociated with signiﬁcant morbidity and mortality rates5 and it is
ne of the most expensive treatments of specialized medicine in
pain.7
International and national studies have assessed labour produc-
ivity losses due to mortality and morbidity for many cancers.8–13
ome of them have focused on speciﬁc types of cancer such as cervi-
al, pancreatic, prostate and a large number on breast cancer.14–17
owever, to our knowledge, few studies have reported information
bout labour productivity losses due to blood cancer: one study
as published two decades ago in Sweden, as part of a cost of
llness analysis and took into account labour productivity losses
ue to morbidity and mortality in acute myeloid leukaemia,18 also
wo articles concerning chronic lymphocytic leukaemia and lym-
homa were recently published in Germany,19,20 and in two articles
bout cancer, leukaemia and lymphoma were found to be amongst
en of the most costly cancers in terms of lost productivity due to
remature cancer-related mortality.8,10
According to the national literature, just one Spanish study men-
ions “diseases of the blood and blood organs and disorders that
ffect immunity and the haematopoietic system” as an area of
tudy and calculates losses in labour productivity due to death.13
etailed information on different haematological diseases, stages
r further treatments such as transplantation were not available in
ny national or international study. In addition, all of them follow
he same methodology, the human capital method, and no speciﬁc
tudy has been published on haematopoietic stem cell transplan-
ation in spite of its increasing incidence in the society.
Our purpose is to provide detailed and useful information on
ffairs relating to one of the economic aspects of blood cancer. More
peciﬁcally, our purpose is to estimate loss of labour productiv-
ty caused by the premature deaths of blood cancer patients who
eceived stem cell transplantation.
ethodsata
Spain does not have a disaggregated national database con-
aining details of treatments and mortality rates of malignantnit. 2015;29(3):178–183 179
haematological diseases. Due to the lack of information, a primary
database was created based on two hospital registries: Haematol-
ogy Department of University Hospital of Virgen del Rocío (Seville)
and Haematology Department of University Hospital of Virgen de
las Nieves of Granada (Granada). The Clinical Research Ethics Com-
mittee of both health centres approved the study. Both hospitals
are referenced in malignant haematological diseases in southeast
and southwest in Spain, respectively. Our sample took into account
the total adult population (over 16 years of age) in the provinces of
Granada and Seville that received HSCT between 2006 and 2011 due
to blood cancer and died before July 2012. Diagnoses of the patients
were leukaemia, lymphoma, multiple myeloma, myelodisplastic
syndrome and other malignant haematological diseases.
Study design
We used standard statistics to describe the sample. Deaths were
calculated in terms of years of potential life lost (YPLL) and years of
potential productive life lost (YPPLL). YPLL was calculated follow-
ing the methodological recommendations of the Spanish National
Statistics Institute (INE) which considers premature death to be the
years a person would have left to live if not for an early mortality
which does not occur at the usual age of death for its collective.21
The range of early mortality was  considered to be between 1 to
69 years of age. Then, we transformed YPLL into YPPLL by estimat-
ing the number of total deaths during working age, in other words,
between 16 and 65 years of age, being 65 the legal age of retire-
ment at the time of the study in Spain. No discount rate was used
for these calculations.
The costs due to early mortality were calculated by applying the
human capital (HC) method to the ﬁeld of health. This approach
points out that negative effects on the health of an individual might
cause undesirable effects on their productivity at work and at home,
and may  result in a loss of leisure time not just for patients but also
for caregivers. So, in the case of a worker who leaves the labour
market due to premature mortality, the potential labour produc-
tivity towards the end of their working life will have been lost by
society.22,23
The average earnings (wage) of a worker are considered a rea-
sonable estimation of labour productivity.23 An incidence approach
was used. We  calculated the number of deaths of working-age indi-
viduals. The age limit for workers to remain in the labour market
was set at 65 years. Once the age of individuals at the time of
death and their expected gross lifetime wages were known, the
present and future ﬂow of productivity lost because of premature
death could be calculated. The expected earnings and the employ-
ment rate were applied to each case, controlled by age and gender
up to the predetermined limit of 65 years. Our calculations were
performed based on the average gross wage ﬁgures contained in
the latest Spanish Wage Structure Survey of the National Statistics
Institute.24 Employment data was  obtained from the latest Labour
Force Survey, also conducted by the National Statistics Institute,
which deﬁnes the employment rate as the percentage of the popu-
lation that is employed in relation to the total population of working
age.25 The costs were actualized for 2009.
Our base case took into account the annual growth rate of labour
productivity in Spain from 2001 to 2012 which was 0.9%,26 and
4.3% as the annual discount rate, which is the mean proﬁtability of
10-year government bonds in Spain from 2002 to 2012.27 This is
coherent with the recent methodological suggestions in economic
evaluations.28 For the sensitivity analysis, we varied annual growth
rates between 0%-2% and annual discount rates between 0%-6%
as standard measures to facilitate comparison with international
literature.28 We  carried out an additional sensitivity analysis for
estimating labour productivity losses using the friction cost (FC)
method. According to this approach, workers who are forced to
1 ac Sanit. 2015;29(3):178–183
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Table 1
Characteristics of patients.
Characteristics Number Rate (%)
Sample 179 100.0
Age  at transplantation (mean; s.d.a; range) 44; 13; 16–67 -
Age  at death (mean; s.d.; range) 45; 13; 16–68 -
Survival days (mean; s.d.; range) 303; 313; 1–1,811 -
Gender
Male 97 54.2
Female 82 45.8
Diagnosis
Acute myeloid leukaemia 51 28.5
Acute lymphoid leukaemia 23 12.8
Hodgkin lymphoma 17 9.5
Non-Hodgkin lymphoma 30 16.7
Multiple myeloma 27 15.0
Myelodisplastic Syndrome 12 6.7
Other 19 10.8
HSCTb according to the type of donor
Autologous 81 45.3
Related allogeneic 67 37.4
Non-related allogeneic 31 17.3
HSCT according to the stem cell source
Peripheral blood 162 90.5
Umbilical cord 12 6.7
Bone marrow 5 2.8
HSCT according to the conditioning regimen
Myeloablative 138 77.1
Non-myeloablative 41 22.9
More than one transplantation
Two HSCT 26 14.5
Three HSCT 1 0.5
a S.d.: Standard deviation
T
N80 M. Ortega-Ortega et al. / G
eave their jobs because of illness or mortality do not cause a large
oss in productivity for society. The only productivity loss occurs
hile the post remains vacant. The authors estimated that this
eriod could last between 2.5 and 3.5 months and it is called the
friction period”.29,30
esults
179 out of 496 patients over 16 years of age underwent trans-
lantations between 2006 and 2011 and had died as of July 2012.
he average age at death was 45. The mean survival time from
he day of the transplantation day was less than one year (303
ays). 54.2% of the patients were male. The disease with the high-
st rate of mortality was leukaemia (41.3%). 45.3% were autologous
ransplantations, 90.5% were peripheral blood transplantations and
7.1% of patients received a myeloablative conditioning regimen.
he descriptive characteristics of the study sample are shown in
able 1.
When distributing the deaths by age and gender, we  found most
f the deaths happened in the 50–59 age group (27.37%) followed
y the 40–49 age group (22.35%). However, detailed information
hows that for patients under 30 years of age, the death rate of
en  was higher than that of women (16.50% vs. 9.76%). On the
ther hand, over 30 years of age, the death rate of men  was lower
han that of women, except for the 50-59 age group (Table 2). As
e can see in Table 2, leukaemia was the disease with the highest
ate of mortality (41.34% of deaths) and the highest rate of death
n men  (46.39%). The YPLL and YPPLL was identiﬁed as 4,268 and
,563 respectively (Table I in Appendix on-line).
In our base case, we estimated D 31.4 million as the cost of
abour productivity lost due to premature mortality. The maximum
nd minimum values obtained in the sensitivity analysis ranged
etween D 61.5 using 2% as the annual growth rate and 0% as the
nnual discount rate, and D 24.7 million using 0% as the annual
rowth rate and 6% as the annual discount rate. The standard rate
haracterized by 1% annual growth rate and 3% as annual discount
ate valued D 36.2 million (Table 3).
The average potential production loss per person was D 185,855,
aking into account our base case. Our results show that 69.5% of the
otal productivity losses are generated by men  (D 21,823,126) and
0.5% by women (D 9,586,397). Additionally, almost 60% of produc-
ivity losses are generated by people who die between 30 and 49
ears of age, and most of them between 30 and 39 (33.7%), in spite of
he fact that in our sample most people died between the ages
f 50 and 59 (Table 4).
Table 5 shows the cost of lost labour productivity by diag-
osis, which was divided into three haematological disease
roups according to their incidence: leukaemia, lymphoma and
able 2
umber of deaths by age group, diagnosis and gender.
Female 
Ages Total % 
≤ 19 1 1.22 
20–29  7 8.54 
30–39  19 23.17 
40–49  19 23.17 
50–59  20 24.39 
60–64  9 10.97 
≥65  7 8.54 
Total  82 100.00 
Diagnosis Total % 
Acute leukaemia 29 35.37 
Lymphoma 23 28.05 
Other  haematological malignancies 30 36.58 
Total  82 100.00 b HSCT: Haematopoietic stem cell transplantation
other haematological malignant diseases. The highest losses were
accounted for by leukaemia (D 15,141,521) because it had the
highest death rate. However, lymphoma accounted the highest
losses per death (D 212,944) despite having the smallest number
of deaths. This is because the average age of death in patients with
lymphoma was the lowest for both males and females in compari-
son with other diagnoses.
In a sensitivity analysis, the FC method showed labour pro-
ductivity losses of D 480,153 for society (D 2,841 per person),
assuming the friction period lasts 2.5 months. It rises to D 672,214
(D 3,977 per person) using 3.5 months as the friction period. The
FC method shows 1.52% of the costs of those determined by
the HC method (Table 6).
Male Total
Total % Total %
7 7.22 8 4.47
9 9.28 16 8.94
18 18.56 37 20.67
21 21.65 40 22.35
29 29.90 49 27.37
10 10.31 19 10.61
3 3.09 10 5.59
97 100.00 179 100.00
Total % Total %
45 46.39 74 41.34
24 24.74 47 26.26
28 28.87 58 32.40
97 100.00 179 100.00
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Table  3
Labour productivity losses (D ) due to premature deaths in blood cancer patients undergoing HSCTa for the year 2009. Human Capital method.
Annual Discount Rate
Growth of Labour Productivity 0% 3% 4.3% 6%
0% 46,209,137 32,489,469 28,613,914 24,712,273
0.9%  52,450,125 35,966,116 31,409,524b 26,856,795
1%  53,063,463 36,252,708 31,617,805 26,994,025
2% 61,533,245 40,762,003 35,164,776 29,656,030
a HSCT: Haematopoietic stem cell transplantation
b Base case
Table 4
Labour productivity losses (D ) due to premature deaths by age group and gender in blood cancer patients undergoing HSCTa for the year 2009. Human Capital method. Base
case  (0.9%, 4.3%).
Age Female Male Total %
≤ 19 239,032 2,603,106 2,842,138 9.05
20-29  1,716,844 3,583,395 5,300,239 16.87
30-39  3,967,202 6,627,791 10,594,993 33.73
40-49  2,547,146 5,509,152 8,056,299 25.65
50-59  1,046,626 3,311,696 4,358,322 13.88
60-  64 69,547 187,986 257,533 0.82
≥  65 - - - -
Total  9,586,397 21,823,126 31,409,524 10.000
Total/person 128,819 232,161 185,855 100.00
a HSCT: Haematopoietic stem cell transplantation
Table 5
Labour productivity losses (D ) due to premature mortality by diagnosis in blood cancer patients undergoing HSCT, for the year 2009. Human Capital method. Base case (0.9%,
4.3%).
Number of deaths
(under 65 years old)
Average female age
of death (s.d.)
Average male age
of death (s.d.)a
Total productivity
losses (D )
Total productivity
losses/person (D )
Acute leukaemia 74 44 (10) 41 (14) 15,141,521 204,615
Lymphoma 46 43 (12) 40 (13) 9,795,424 212,944
Other haematological malignancies 49 52 (14) 52 (12) 6,472,579 132,093
a S.d.: Standard deviation
b HSCT: Haematopoietic stem cell transplantation
Table 6
Sensitivity analysis of labour productivity losses (D ) in blood cancer patients under-
going a HSCTa for the year 2009.
Labour productivity
losses (D )
Human Capital method. Base case (0.9%; 4.3%) 31,409,524
Friction Cost method (2.5 months) 480,152
Friction Cost method (3.5 months) 672,214
FCb (2.5 months) vs. HCc 1.52%
a HSCT: Haematopoietic stem cell transplantation
D
3
b
2
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both have been criticized.33 Some authors consider that HC methodb FC: Friction cost
c HC: Human capital
iscussion
The IARC projected an increased incidence of cancer in Europe of
2% beginning in the mid-80s.2 Haematological malignancies has
een one of cancers with the biggest increases in incident rate. In
012, 186.7 thousand new cases of blood cancer were estimated in
he EU-27 and 14.9 thousand in Spain.2 The predictions for Spain
re now to reach 17.2 thousand new cases in 2015.3
This increased incidence makes it necessary to study the costs
ssociated with different treatments to discover the economic
mpact on society (direct costs, indirect costs and informal care
osts). Particularly, the European Society for Medical Oncology con-
luded, after reviewing many international articles, that labour
roductivity costs accounted for more than two-thirds of the total
osts of cancer.9 However, few studies have been published relat-
ng to non-health care costs in the haematologic area, even thoughstem cell transplantation is an essential part of the treatment for
increasing survival rate of patients and one of the most expen-
sive therapies in Spain7. Our study partially ﬁlls the knowledge
gap highlighted by many authors on non-health care costs in the
haematologic area.19,20,31,32
We examined the potential labour productivity loss that society
could gain if the transplantations were effective enough to allow
oncohaematologic patients to survive and continue working in the
labour market. This subgroup of patients received the best available
treatment according to the clinical protocol, but premature mor-
tality and productivity losses are still high. We  conclude that, in a
sample of 179 transplanted patients, 3,563 years of potential pro-
ductivity have been lost and that the productivity losses for society
because of early death have reached D 31.4 million. In other words,
our ﬁndings suggest that society could save on average D 185,855
per surviving patient if they could have a quality of life good enough
to continue working in the labour market. 69.5% of the total labour
productivity losses are accounted for by men. This is due to the
incorporation of economic information such as labour force par-
ticipation and wage rates into the estimates, which usually inﬂate
male costs relative to female cost.8,10–12 People who  die between
30 and 49 years of age and leukaemia patients generate the higher
losses. In contrast, losses are smaller using the Friction Cost method,
representing just the 1.52% of losses showed by the Human Capital
method. There is no agreement about which method is the best andoverestimates the results,29,30 however it is solidly grounded in
neoclassical economic framework. In contrast, FC approach breaks
basic axioms of economic theory due to the absence of a theoretical
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ramework. This could possibly be one of the underlying reasons for
he increased use of HC in applied studies, although there are other
easons that hamper the empirical application of the friction cost
ethod.34
According to the international literature, which follows the
uman Capital method, blood cancer is one of the most costly
ancers in terms of cost of lost productivity due to premature mor-
ality. A recent article published by Hanly et al.8 estimated the
remature mortality costs of the 10 most common cancers in Ire-
and. They estimated that the most costly cancer in males, was
eukaemia (D 426,247 per death) followed by non-Hodgkin’s lym-
homa in the third position (D 385,480 per death). Non-Hodgkin’s
ymphoma was the third highest in females (D 157,289 per death).
im et al.35 published a similar article studying the economic bur-
en of cancer in Korea. Leukaemia was the second most costly
ancer ($167,000 per death), Hodgkin’s lymphoma was estimated
t $157,000, non-Hodgkin’s lymphoma at $128,000, and multiple
yeloma at $89,000 per death. Bradley et al.10 estimated cancer-
elated productivity costs in US and they pointed out that Hodgkin’s
ymphoma was the second most expensive ($544,118 per death).
eukaemia was calculated at $240,387 and non-Hodgkin’s lym-
homa at $219,407 per death. Just two studies have focused on
he estimation of loss labour productivity due to premature mor-
ality associated with blood cancer, speciﬁcally in acute myeloid
eukaemia in Sweden in 1994 and malignant lymphoma in Ger-
any in 2000.18,19 Loss per patient could not be calculated because
f the lack information in both articles about the number of deaths
f people under 65 years of age. Costs are very different depending
n the country, and these differences are due to the labour mar-
et conditions and wages. Also, variables, such as type of cancer,
ethodology used, age or gender, inﬂuence the results and make
omparison between studies more difﬁcult.10,14,33
Our results are in line with those reported by other national
tudies. Anton˜anzas et al.12 concluded that labour productivity
osses due to premature mortality are distributed in an unequal
ay by gender in oncologic patients, as they are higher in men.
heir results show an average labour productivity loss per pre-
ature death due to cancer of D 92,592 (prices actualized to the
ear 2003). In the same line, Oliva et al.13 estimated D 90,550 per
atient in 2011. However, their further study pointed out the dif-
erences in cost depending on the type of cancer.14 The losses were
alculated as D 69,332 and D 52,486 per premature death in cervi-
al and breast cancer, respectively. They also compared HC vs. FC
ethods, obtaining sharp differences between them. Just their ﬁrst
tudy took into account haematological diseases, estimating a total
abour productivity loss of D 189,828 per premature death.13 These
esults are totally in agreement with ours.
Several limitations of our study should be noted. The ﬁrst
imitation is our limited population on transplanted patients. This
eans that our results could not be extrapolated to the total blood
ancer population in working age. Future directives for research
ould focus on amplifying our analysis using other Spanish health
entres’ registries to increase the external validity of the present
tudy and also using non-transplanted patients to compare results.
he second limitation is related to the estimated average survival
ime. Given the short study period for people who had transplan-
ation during 2010 and 2011, there could be a possible bias due to
eaths out of the observational period. However, it is expected to
e small. Thirdly, given the complexity of modelling employment
ates for an uncertain future and following other studies, current
mployment rates were used in our analysis. Finally, the Friction
ost method determines the friction period as 2.5 or 3.5 months,
owever this period could be longer or shorter depending on the
conomic cycle of each country and its market labour.29,30,33
Our study is unique because the collection of premature mor-
ality data is novel, takes into account the total transplantednit. 2015;29(3):178–183
population with blood cancer in two provinces, ﬁlls the lack of
knowledge due to limited public information in Spain and captures
three important domains: diagnosis, gender and age. Thus, this is
the ﬁrst study to examine labour productivity loss in a subgroup of
transplanted patients.
As some authors have remarked, it is necessary to use a social
perspective to gain in-depth knowledge of blood cancer treatment
costs.31,32 Our results provide new information about labour pro-
ductivity losses due to premature mortality of blood cancer patients
who received a stem cell transplantation and add useful informa-
tion about economic dimension that is valuable to society and
decision-makers. They could be useful for future cost of illness
studies in order to complement their epidemiological information.
What is known about subject?
Annual number of deaths due to blood cancer is rising every
year. However, many  few international studies have explored
in-depth labour productivity losses due to premature mortal-
ity and none of them have focused on further treatment as
stem cell transplantation. We  give primary information to the
international and national literature.
What does this study add to the literature?
This paper gives further information on labour productiv-
ity losses due to premature mortality in Spanish blood cancer
patients, speciﬁcally on patients undergoing stem cell trans-
plantation as part of their treatment. These non-medical costs
of blood cancer could be taking into account by policy-makers
for future policies. These results are very useful for future
Spanish and international cost of illness studies due to the
primary and disaggregated data.
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